Novo Nordisk announced a major shift on Monday, confirming that it will cut the US price of its injectable weight-loss drug Wegovy while doubling down on its upcoming oral version.
The company said it is preparing to "go all in" on its new weight-loss pill as it tries to regain lost ground in a rapidly growing market.
